Actavis Launches U.S. Generic Specialty Injectable Portfolio - Quick Facts

(RTTNews) - Specialty pharmaceutical company Actavis plc (ACT) announced the launch of a leading portfolio of generic specialty injectable medications to be marketed to hospitals across the U.S.

Actavis will immediately begin marketing about 20 injectable products across a number of therapeutic categories in the U.S. The company will become a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa.

Actavis noted that these injectable products were previously marketed in the U.S. by Sagent Pharmaceuticals, Inc. since 2010. However, Actavis has now regained U.S. marketing rights to the products following the expiration of the Sagent agreement on December 31, 2014.

Actavis also said it has an industry leading specialty injectable pipeline, with about 20 new filings under review at the U.S. Food and Drug Administration (FDA), as well as more than 50 additional projects currently in development.